BRAF V600 Mutation Analysis
Use
The BRAF V600 Mutation Analysis is used as an independent predictor of colorectal cancer (CRC) patient responsiveness to EGFR inhibitor therapy. Additionally, it assists with differentiating microsatellite instability high (MSI-H) hereditary non-polyposis colon cancer (HNPCC) from sporadic cancer cases.
Special Instructions
FFPE block is preferred for specimen submission, although unbaked slides are acceptable. It is important to include a surgical pathology report with the sample.
Limitations
The test may be limited by factors such as improper specimen labeling, insufficient tissue, insufficient tumor burden, or insufficient DNA isolated, which are causes for specimen rejection.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
FFPE Block, 10% NBF Fixed
Storage Instructions
Store between 15°C to 25°C
Causes for Rejection
Improper specimen labeling; Insufficient tissue; Insufficient tumor burden; Insufficient DNA isolated
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinite |